首页 | 本学科首页   官方微博 | 高级检索  
     


Post‐renal transplant erythrocytosis: A case report
Authors:Mavel Almonte  Luis Velásquez‐Jones  Saúl Valverde  Bruce Carleton  Mara Medeiros
Affiliation:1. Departamento de Nefrología, Hospital Infantil de México Federico Gómez, Mexico City, Mexico;2. Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, BC, Canada;3. Division of Translational Therapeutics, Department of Paediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada;4. Child & Family Research Institute, Vancouver, BC, Canada;5. Laboratorio de Investigación en Nefrología y Metabolismo Mineral, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
Abstract:PTE is defined as hematocrit >51% or hemoglobin >17 g/dL after renal transplantation. Risk factors include native kidneys with adequate erythropoiesis pretransplant, smoking, renal artery stenosis, and cyclosporine treatment. We report the case of a 14‐yr‐old female kidney transplant patient, with triple therapy immunosuppression and stable graft function who developed PTE at 12 months post‐transplant with hemoglobin 17.3 g/dL, hematocrit 54.2%, stable graft function, and normotensive with normal cardiac echocardiogram and erythropoietin levels. The only risk factor found was tobacco use. As she had no spontaneous improvement, enalapril treatment was started at 19 months post‐transplant with a hemoglobin level of 17.5 g/dL and hematocrit 53%; by 23 months post‐transplant, hemoglobin lowered to 15 g/dL and hematocrit to 44.5% and continued to be in normal range thereafter. PTE is a rare condition in childhood and can be successfully treated with enalapril.
Keywords:erythrocytosis  kidney transplantation  immunosuppression  enalapril  erythropoietin
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号